Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance.

Authors :: Chou S
Source :: Antiviral research [Antiviral Res] 2020 Apr; Vol. 176, pp. 104711. Date of Electronic Publication: 2020 Jan 12.
Publication Year :: 2020
Abstract: Cytomegalovirus (CMV) drug resistance mutation maps are updated with recent information for polymerase inhibitors, the terminase inhibitor letermovir and the UL97 kinase inhibitor maribavir. Newly mapped mutations and their phenotypes provide more detail on cross-resistance properties and suggest the need to expand the CMV gene regions covered in diagnostic testing. Next-generation deep sequencing technology offers a more sensitive, higher resolution view of emerging antiviral resistance and is recommended for use in clinical trials. Issues of standardization and diagnostic utility in comparison with traditional Sanger sequencing remain unresolved. Quality control is important for the accurate and reproducible detection of mutant viral populations in clinical specimens.<br /> (Copyright © 2020 Elsevier B.V. All rights reserved.)

Subjects :: Clinical Trials as Topic
Cytomegalovirus Infections virology
Genotype
Genotyping Techniques
High-Throughput Nucleotide Sequencing
Humans
Mutation drug effects
Viral Proteins genetics
Antiviral Agents pharmacology
Cytomegalovirus drug effects
Cytomegalovirus genetics
Cytomegalovirus Infections diagnosis
Drug Resistance, Multiple, Viral

Full Text Access

Tools